Safety of biologics and Janus kinase inhibitors in inflammatory bowel disease patients with low cardiovascular risk. - Patel P; Iqbal O; Mohananey D; Bajwa S; Khani M; Luo J; Stein DJ; Kochhar GS; Hashash JG; Mansoor E; Cross RK; Sinh P (Crohn's & colitis 360, 2026)